Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
暂无分享,去创建一个
M. Landray | P. Horby | W. Lim | C. Brightling | J. Emberson | J. Baillie | T. Jaki | K. Rowan | J. Day | G. Thwaites | L. Peto | N. Staplin | E. Spata | G. Pessoa-Amorim | M. Campbell | L. Chappell | E. Juszczak | M. Mafham | R. Haynes | M. Buch | V. Jeebun | R. Sarkar | A. Montgomery | A. Ashish | R. Stewart | B. Rudran | Redmond Tully | K. Thomas | K. Jeffery | A. Mumford | David Chadwick | M. Sharafat | Saul N Furst | R. Haynes | Christopher E. Brightling | L. Chappell | D. Chadwick | R. Tully | Saul N Furst | C. Brightling
[1] Andreas Lundh. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. , 2021, The New England journal of medicine.
[2] Patricia A. H. Williams,et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, The Lancet.
[3] N. Meyer,et al. Covid-19 controversies: the tocilizumab chapter , 2021, BMJ.
[4] Á. Avezum,et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial , 2021, BMJ.
[5] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 , 2021, medRxiv.
[6] D. Leaf,et al. Tocilizumab in Covid-19. , 2020, The New England journal of medicine.
[7] Colin Smith,et al. Tissue-Specific Immunopathology in Fatal COVID-19 , 2020, American journal of respiratory and critical care medicine.
[8] J. McCanny,et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England , 2020, medRxiv.
[9] Eric A. Meyerowitz,et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.
[10] R. Porcher,et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[11] M. Massari,et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[12] Jennifer L. Bell,et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, The Lancet.
[13] Arthur S Slutsky,et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.
[14] I. Douglas,et al. Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia , 2020, medRxiv.
[15] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[16] Arthur S Slutsky,et al. Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials , 2020, Trials.
[17] Jennifer L. Bell,et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.
[18] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[19] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.
[20] C. Whittaker,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[21] Hong Jiang,et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up , 2020, Journal of Infection.
[22] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[23] Daishi Tian,et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China , 2020 .
[24] K. Reinhart,et al. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. , 1999, Critical care medicine.